IgM, not IgG, a key for HIV vaccine

Vaccine

Volumn 27, Issue 9, 2009, Pages 1287-1288

  Yang, Quan en ^a  

^a NONE   (United States)

Author keywords

Complement; HIV antigens; HIV therapy; HIV vaccine; IgM; Preformed natural antibody

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; LETTER; PRIORITY JOURNAL;

AIDS VACCINES; ANTIBODY FORMATION; DRUG DESIGN; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRAL VACCINES;

EID: 59649090408     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.030     Document Type: Letter

References (15)

1. Yang Q.E. Eradication of HIV in infected patients: some potential approaches. Med Sci Monit 10 7 (2004) RA155-RA165
2. Yang Q.E., Li K.G., and Mikovits J.A. Eradication of human immunodeficiency virus type 1-infected cells by a combination of antimetabolic cytotoxic chemotherapy and antiviral chemotherapy in vitro: a pilot study. J Infect Dis 186 5 (2002) 706-709
3. Stolte I.G., Dukers N.H., Geskus R.B., Coutinho R.A., and de Wit J.B. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 18 2 (2004) 303-309
4. McCarthy M. HIV vaccine fails in phase 3 trial. Lancet 361 9359 (2003) 755-756
5. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 205 1 (2008) 7-12
6. Takeda A., Tuazon C.U., and Ennis F.A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242 4878 (1988) 580-583
7. Poignard P., Sabbe R., Picchio G.R., Wang M., Gulizia R.J., Katinger H., Parren P.W., Mosier D.E., and Burton D.R. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10 4 (1999) 431-438
8. Spear G.T., Olinger G.G., Saifuddin M., and Gebel H.M. Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement. J Acquir Immune Defic Syndr 26 2 (2001) 103-110
9. Arthur L.O., Bess Jr. J.W., Sowder II R.C., Benveniste R.E., Mann D.L., Chermann J.C., and Henderson L.E. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258 5090 (1992) 1935-1938
10. Neil S.J., McKnight A., Gustafsson K., and Weiss R.A. HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation. Blood 105 12 (2005) 4693-4699
11. Lobo P.I., Schlegel K.H., Yuan W., Townsend G.C., and White J.A. Inhibition of HIV-1 infectivity through an innate mechanism involving naturally occurring IgM anti-leukocyte autoantibodies. J Immunol 180 3 (2008) 1769-1779
12. Daar E.S., Moudgil T., Meyer R.D., and Ho D.D. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 324 14 (1991) 961-964
13. Notarangelo L.D., Lanzi G., Peron S., and Durandy A. Defects of class-switch recombination. J Allergy Clin Immunol 117 4 (2006) 855-864
14. Nagaoka H., Muramatsu M., Yamamura N., Kinoshita K., and Honjo T. Activation-induced deaminase (AID)-directed hypermutation in the immunoglobulin Smu region: implication of AID involvement in a common step of class switch recombination and somatic hypermutation. J Exp Med 195 4 (2002) 529-534
15. Schrader C.E., Linehan E.K., Mochegova S.N., Woodland R.T., and Stavnezer J. Inducible DNA breaks in Ig S regions are dependent on AID and UNG. J Exp Med 202 4 (2005) 561-568